Connect Biopharma (CNTB) H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference summary

Leadership and strategic direction

• New CEO and President appointed to bring drug development and investment expertise.

• Management structure and company focus have been overhauled to prioritize rademikibart.

• Shifted focus to acute and chronic indications for respiratory diseases.

Rademikibart clinical profile and differentiation

• Rademikibart is a next-generation IL-4 antibody with tighter binding and unique structural features.

• Demonstrates rapid and significant improvement in airway function, with effects seen within 24 hours.

• Lacks the eosinophil-related adverse events seen with Dupixent, instead lowering eosinophil counts.

Clinical development and trial design

• Phase 2 trials will target patients experiencing acute exacerbations of asthma or COPD.

• Study design includes randomization during active exacerbation and a four-week primary endpoint.

• The trial is powered to detect a 50% reduction in secondary exacerbations, aiming for even greater benefit.

• Data collection methods include early FEV1 measurement and home spirometry, revealing rapid onset.